# Olorofim Aspergillus Infection Study

> **NCT05101187** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **F2G Biotech GmbH** · enrollment: 225 (estimated)

## Conditions studied

- Invasive Aspergillosis

## Interventions

- **DRUG:** Olorofim
- **DRUG:** AmBisome®

## Key facts

- **NCT ID:** NCT05101187
- **Lead sponsor:** F2G Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-31
- **Primary completion:** 2025-11-18
- **Final completion:** 2026-11-01
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101187, "Olorofim Aspergillus Infection Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05101187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*